Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Brain-Targeted Codelivery of Bcl-2/Bcl-xl and Mcl-1 Inhibitors by Biomimetic Nanoparticles for Orthotopic Glioblastoma Therapy
Wenya He, Xiaozhe Li, Marco Morsch, et al.
ACS Nano (2022) Vol. 16, Iss. 4, pp. 6293-6308
Closed Access | Times Cited: 77

Showing 1-25 of 77 citing articles:

Where Is Nano Today and Where Is It Headed? A Review of Nanomedicine and the Dilemma of Nanotoxicology
Cátia Domingues, Ana Cláudia Paiva‐Santos, Carmen Alvarez‐Lorenzo, et al.
ACS Nano (2022) Vol. 16, Iss. 7, pp. 9994-10041
Closed Access | Times Cited: 126
Immune Exosomes Loading Self-Assembled Nanomicelles Traverse the Blood–Brain Barrier for Chemo-immunotherapy against Glioblastoma
Jiwei Cui, Xue Wang, Jinge Li, et al.
ACS Nano (2023) Vol. 17, Iss. 2, pp. 1464-1484
Closed Access | Times Cited: 122
Exosomes based strategies for brain drug delivery
Fawad Ur Rehman, Yang Liu, Meng Zheng, et al.
Biomaterials (2022) Vol. 293, pp. 121949-121949
Closed Access | Times Cited: 117
Cancer cell-mitochondria hybrid membrane coated Gboxin loaded nanomedicines for glioblastoma treatment
Yan Zou, Yajing Sun, Yibin Wang, et al.
Nature Communications (2023) Vol. 14, Iss. 1
Open Access | Times Cited: 83
An optimized ionizable cationic lipid for brain tumor-targeted siRNA delivery and glioblastoma immunotherapy
Shuhan Liu, Ji Liu, Haisong Li, et al.
Biomaterials (2022) Vol. 287, pp. 121645-121645
Closed Access | Times Cited: 78
Targeted liposomes for combined delivery of artesunate and temozolomide to resistant glioblastoma
Muhammad Ismail, Wen Yang, Yanfei Li, et al.
Biomaterials (2022) Vol. 287, pp. 121608-121608
Closed Access | Times Cited: 76
Revolutionizing Neurocare: Biomimetic Nanodelivery Via Cell Membranes
Jun Liao, Lidong Gong, Qingqiang Xu, et al.
Advanced Materials (2024) Vol. 36, Iss. 26
Closed Access | Times Cited: 28
Brain-Targeting Drug Delivery Systems: The State Of The Art In Treatment Of Glioblastoma
Bo Sun, Rong Li, Ning Ji, et al.
Materials Today Bio (2025) Vol. 30, pp. 101443-101443
Open Access | Times Cited: 3
Advanced Nanoparticle Engineering for Precision Therapeutics of Brain Diseases
Muhammad Ismail, Jiayi Liu, Ningyang Wang, et al.
Biomaterials (2025) Vol. 318, pp. 123138-123138
Closed Access | Times Cited: 2
Non-invasive PTEN mRNA brain delivery effectively mitigates growth of orthotopic glioblastoma
Yanjie Liu, Dongya Zhang, Yang An, et al.
Nano Today (2023) Vol. 49, pp. 101790-101790
Closed Access | Times Cited: 34
Radiation-Triggered Selenium-Engineered Mesoporous Silica Nanocapsules for RNAi Therapy in Radiotherapy-Resistant Glioblastoma
Xianglong Tang, Zhen Wang, Yandong Xie, et al.
ACS Nano (2023) Vol. 17, Iss. 4, pp. 4062-4076
Closed Access | Times Cited: 32
Homotypic Membrane-Enhanced Blood–Brain Barrier Crossing and Glioblastoma Targeting for Precise Surgical Resection and Photothermal Therapy
Hang Zhang, Shujuan Guan, Tianxiang Wei, et al.
Journal of the American Chemical Society (2023) Vol. 145, Iss. 10, pp. 5930-5940
Closed Access | Times Cited: 32
Nanoparticles Mediated the Diagnosis and Therapy of Glioblastoma: Bypass or Cross the Blood–Brain Barrier
Xiaowei Song, Haisheng Qian, Yongqiang Yu
Small (2023) Vol. 19, Iss. 45
Closed Access | Times Cited: 25
PEG length effect of peptide-functional liposome for blood brain barrier (BBB) penetration and brain targeting
Qiuli Du, Yan Liu, Mengyu Fan, et al.
Journal of Controlled Release (2024) Vol. 372, pp. 85-94
Closed Access | Times Cited: 13
Peptide-Hitchhiking for the Development of Nanosystems in Glioblastoma
Francisco Branco, Joana Cunha, Maria Mendes, et al.
ACS Nano (2024) Vol. 18, Iss. 26, pp. 16359-16394
Open Access | Times Cited: 12
Senolytic treatment alleviates doxorubicin‐induced chemobrain
Vivekananda Budamagunta, Ashok Kumar, Asha Rani, et al.
Aging Cell (2024) Vol. 23, Iss. 2
Open Access | Times Cited: 9
Targeting Myeloid Leukemia-1 in Cancer Therapy: Advances and Directions
Hongguang Deng, Yu Han, Liang Liu, et al.
Journal of Medicinal Chemistry (2024) Vol. 67, Iss. 8, pp. 5963-5998
Closed Access | Times Cited: 8
Recent Advances in Biomimetic Strategies for the Immunotherapy of Glioblastoma
Haoyu You, Shuo Geng, Shangkuo Li, et al.
Biomaterials (2024) Vol. 311, pp. 122694-122694
Closed Access | Times Cited: 8
Stimuli-Responsive Polymeric Nanocarriers Accelerate On-Demand Drug Release to Combat Glioblastoma
Muhammad Ismail, Yibin Wang, Y. M. Li, et al.
Biomacromolecules (2024)
Closed Access | Times Cited: 8
Utilization of nanotechnology to surmount the blood-brain barrier in disorders of the central nervous system
Qian Luo, Jiaying Yang, Mei Yang, et al.
Materials Today Bio (2025) Vol. 31, pp. 101457-101457
Open Access | Times Cited: 1
Combined Strategies for Nanodrugs Non-invasively Overcoming Blood-Brain Barrier and Actively Targeting Glioma Lesions
Yuanyuan Liu, Haigang Wu, Gaofeng Liang
Biomaterials Research (2025) Vol. 29
Open Access | Times Cited: 1
Challenges and Material Innovations in Drug Delivery to Central Nervous System Tumors
Zhenyu Gong, Dairan Zhou, Dejun Wu, et al.
Biomaterials (2025) Vol. 319, pp. 123180-123180
Closed Access | Times Cited: 1
ApoE-mediated systemic nanodelivery of granzyme B and CpG for enhanced glioma immunotherapy
Jingjing Wei, Di Wu, Yu Shao, et al.
Journal of Controlled Release (2022) Vol. 347, pp. 68-77
Closed Access | Times Cited: 37
Biomimetic Dp44mT-nanoparticles selectively induce apoptosis in Cu-loaded glioblastoma resulting in potent growth inhibition
Muhammad Ismail, Wen Yang, Yanfei Li, et al.
Biomaterials (2022) Vol. 289, pp. 121760-121760
Closed Access | Times Cited: 31
The first-in-class ERK inhibitor ulixertinib shows promising activity in mitogen-activated protein kinase (MAPK)-driven pediatric low-grade glioma models
Romain Sigaud, Lisa Rösch, Charlotte Gatzweiler, et al.
Neuro-Oncology (2022) Vol. 25, Iss. 3, pp. 566-579
Open Access | Times Cited: 29
Page 1 - Next Page

Scroll to top